Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or more who had previously untreated microinvasive SCC, providing they satisfied both of the following conditions:~  * tumor invasion into the papillary dermis (Clark level II) according to a biopsy specimen and~ * difficulty in surgical excision because of health problems (bleeding tendency or cardiac problems)~Exclusion Criteria:~* pregnancy or lactation~* active systemic infectious disease~* other inflammatory, infectious, or neoplastic skin diseases in the treated area~* allergy to MAL,other topical photosensitizers, or excipients of the cream~* history of photosensitivity~* use of immunosuppressive or photosensitizing drugs~* participation in any other investigational study in the preceding 30 days~* history or indicators of poor compliance~* Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- AFL-PDT (Type: EXPERIMENTAL): Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
- MAL-PDT (Type: ACTIVE_COMPARATOR): Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).